New research is providing a more precise prediction of COVID-19 severity that can be found by looking at autoantibodies in the nasal cavity, leading to more personalized treatment plans.

Sarepta Therapeutics has ended development of a late-phase Duchenne muscular dystrophy (DMD) drug candidate over a safety problem. The safety signal deprived Sarepta of a near-term shot at accelerated ...